Lipid conjugates in the treatment of allergic rhinitis
View Patent ↗Provided herein are methods of treating, suppressing, inhibiting, or preventing allergic rhinitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
1. A method of treating or preventing allergic rhinitis in a subject, comprising the step of administering to said subject a phospholipid-glycosaminoglycan conjugate represented by the structure of the general formula (A):
wherein
L is a phospholipid;
Z is nothing;
Y is nothing;
X is glycosaminoglycan; and
n is a number from 1 to 1000.
2. The method according to claim 1 , wherein said glycosaminoglycan is hyaluronic acid.
3. The method according to claim 1 , wherein L is phosphatidylethanolamine.
4. The method according to claim 3 , wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
5. The method according to claim 1 , wherein treating or preventing allergic rhinitis comprises alleviating or preventing one or more of the symptoms selected from the group consisting of nasal congestion, rhinorrhea, frontal headache, post-nasal drip, sneezing, nasal itch, itching ears/palate and cough.
6. The method according to claim 5 , wherein said one or more of the symptoms is selected from the group consisting of nasal congestion, rhinorrhea, sneezing and nasal itch.
7. The method according to claim 5 , wherein said one or more of the symptoms comprises headache.
8. The method according to claim 5 , wherein said one or more of the symptoms comprises cough.
9. The method according to claim 1 , wherein said subject is concurrently taking an asthma rescue medication and said treatment or prevention decreases the subject's need for the asthma rescue medication.
10. The method according to claim 1 , wherein the step of administering comprises intranasal administration.
11. The method according to claim 1 , wherein the step of administering comprises intranasal administration.
12. The method according to claim 1 , wherein treating or preventing allergic rhinitis comprises reducing the levels of a cytokine selected from the group consisting of IL-5, IL-13, MCP-1, TNF-α, IL-8 and eotaxin.
13. The method according to claim 1 , wherein treating or preventing allergic rhinitis comprises reducing eosinophil counts.
14. The method according to claim 1 , wherein said compound is represented by the structure of the general formula (I):
wherein
R 1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
R 2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
Y is nothing;
X is glycosaminoglycan; and
n is a number from 1 to 1,000.
15. The method of claim 1 , wherein said glycosaminoglycan is selected from the group consisting of hyaluronic acid, heparin, heparan sulfate, chondrotin sulfate, keratan, keratan sulfate, dermatan sulfate or a derivative thereof.
16. The method of claim 1 , wherein said glycosaminoglycan has a molecular weight of between 5 kD and 20 kD.
17. The method of claim 16 , wherein said glycosaminoglycan is hyaluronic acid.